Results 91 to 100 of about 13,617 (225)
Determinants of Poor Health‐Related Quality of Life in Patients With Food Allergy
Allergy, EarlyView.Machine‐learning analysis of 502 well‐characterised food‐allergic patients was used to identify key determinants of poor FA‐HRQL, defined as FAQLQ ≥ 5. The most relevant predictors were adult age, female sex, multiple food allergies, severe reactions, need for urgent care, onset before 18 years, and longer disease duration.
Rosialzira Natasha Vera‐Berrios +24 more
wiley +1 more source
Long-Term Omalizumab use in the Treatment of Exercise-Induced Anaphylaxis
Allergy & Rhinology, 2017 Reported is a case of a 39-year-old male who was diagnosed with exercise-induced anaphylaxis (EIA). He was initially treated prophylactically with fexofenadine, montelukast, and ranitidine. He also used an epinephrine autoinjector as needed.
Mark R. Peterson D.O. +1 more
doaj +1 more source
Omalizumab for Chronic Urticaria: A Case Series and Overview of the Literature
Case Reports in Dermatology, 2012 Omalizumab is a recombinant humanized monoclonal antibody that blocks the high-affinity Fc receptor of IgE. Omalizumab has been approved for the treatment of moderate to severe asthma; however, there is currently more and more data showing promising ...
Ilya Ivyanskiy +2 more
doaj +1 more source
Omalizumab in allergic bronchopulmonary aspergillosis in patients with cystic fibrosis
, 2018 Moshe Ashkenazi,1,2 Saray Sity,2 Ifat Sarouk,1,2 Bat El Bar Aluma,1,2 Adi Dagan,1,2 Yael Bezalel,1,2 Lea Bentur3 Kris De Boeck,4 Ori Efrati1,2 1Pediatric Pulmonology and National CF Center,
Sarouk I +8 more
core
Allergy, EarlyView.ABSTRACT Mucosal surfaces are sites of highly dynamic interactions among epithelial and immune cells, environmental exposures, particularly dietary inputs, and the diverse microbial communities and their metabolites. These elements continually influence each other to maintain homeostasis and ensure appropriate immune discrimination between pathogens ...
Clara Delaroque +5 more
wiley +1 more source
Current and future applications of the anti-IgE antibody omalizumab
, 2008 Cristoforo Incorvaia1, Marina Mauro2, Gian Galeazzo Riario-Sforza1,Franco Frati3, Francesco Tarantini4, Maurizio Caserini41Allergy/Pulmonary rehabilitation, ICP Hospital, Milan, Italy; 2Allergy Unit, Sant’Anna Hospital, Como, Italy; 3University
Maurizio Caserini +5 more
core
How to evaluate a patient's response to anti-IgE
European Respiratory Review, 2007 Omalizumab, an anti-immunoglobulin E antibody, is indicated in the European Union (EU) as add-on therapy for patients with severe persistent allergic asthma whose symptoms persist, despite receiving optimised treatment with high-dose inhaled ...
S. T. Holgate
doaj
A review of omalizumab for the management of severe asthma
, 2016 Ching-Hsiung Lin,1–3 Shih-Lung Cheng4,5 1Division of Chest Medicine, Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan, Republic of China; 2Department of Respiratory Care, College of Health Sciences, Chang Jung ...
Cheng SL, Lin CH
core
Algorithms in Allergy: Hereditary Angioedema
Allergy, EarlyView.
Konrad Bork +3 more
wiley +1 more source
Impact of Biologics on Oscillometry Defined Small Airway Dysfunction in Uncontrolled Asthma
Clinical &Experimental Allergy, EarlyView.Forced oscillometry technique defined small airways dysfunction as a treatable trait in asthma. Monoclonal antibodies can improve small airways dysfunction, but their effects vary by mechanism of action. ABSTRACT Small airways dysfunction (SAD) is a recognised treatable trait within severe asthma, associated with worse symptom control and increased ...
Robert Greig +3 more
wiley +1 more source